Income Statement for VOR

	Vor Biopharma Inc. (VOR)
	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014
Balance Sheet Date			2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31	2023-Sep-30	2023-Jun-30	2023-Mar-31	2022-Dec-31	2022-Sep-30	2022-Jun-30	2022-Mar-31	2021-Dec-31	2021-Sep-30	2021-Jun-30	2021-Mar-31
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023	Q3-FY2023	Q2-FY2023	Q1-FY2023	Q4-FY2022	Q3-FY2022	Q2-FY2022	Q1-FY2022	Q4-FY2021	Q3-FY2021	Q2-FY2021	Q1-FY2021
Total Revenue
QoQ%
YoY%
Cost Of Revenue
Gross Profit
Gross Margin
Operating Expenses			35,960,000$	28,107,000$	274,284,000$	33,291,000$	31,311,000$	28,513,000$	29,035,000$	32,326,000$	28,124,000$	35,316,000$	32,174,000$	30,422,000$	24,725,000$	24,101,000$	21,792,000$	22,800,000$	18,306,000$	18,602,000$	18,380,000$	13,730,000$	15,663,000$	11,785,000$	8,040,000$	7,878,000$
Operating Income			(35,960,000$)	(28,107,000$)	(274,284,000$)	(33,291,000$)	(31,311,000$)	(28,513,000$)	(29,035,000$)	(32,326,000$)	(28,124,000$)	(35,316,000$)	(32,174,000$)	(30,422,000$)	(24,725,000$)	(24,101,000$)	(21,792,000$)	(22,800,000$)	(18,306,000$)	(18,602,000$)	(18,380,000$)	(13,730,000$)	(15,663,000$)	(11,785,000$)	(8,040,000$)	(7,878,000$)
Operating Margin
Interest Income			2,795,000$	1,731,000$	537,000$	805,000$	599,000$	954,000$	1,196,000$	1,522,000$	1,863,000$	2,126,000$	2,195,000$	1,989,000$	815,000$	313,000$	133,000$	63,000$	54,000$	48,000$	10,000$	7,000$	0$	0$	0$	29,000$
Interest Expenses
Income Before Tax			1,722,858,000$	(812,684,000$)	(1,573,669,000$)	(32,486,000$)	(30,712,000$)	(27,559,000$)	(27,839,000$)	(30,804,000$)	(26,261,000$)	(33,190,000$)	(29,979,000$)	(28,433,000$)	(23,910,000$)	(23,788,000$)	(21,659,000$)	(22,737,000$)	(18,252,000$)	(18,554,000$)	(18,370,000$)	(13,723,000$)	(15,663,000$)	(11,785,000$)	(8,040,000$)	(7,849,000$)
Tax Expenses
Net Income			1,722,858,000$	(812,684,000$)	(1,573,669,000$)	(32,486,000$)	(30,712,000$)	(27,559,000$)	(27,839,000$)	(30,804,000$)	(26,261,000$)	(33,190,000$)	(29,979,000$)	(28,433,000$)	(23,910,000$)	(23,788,000$)	(21,659,000$)	(22,737,000$)	(18,252,000$)	(18,554,000$)	(18,370,000$)	(13,723,000$)	(15,663,000$)	(11,785,000$)	(8,040,000$)	(7,849,000$)
Profit Margin
TTM
Earnings to Minority																						1,228,000$	2,170,000$	2,185,000$	855,000$	715,000$
Earnings to Common Shareholders			1,722,858,000$	(812,684,000$)	(1,573,669,000$)	(32,486,000$)	(30,712,000$)	(27,559,000$)	(27,839,000$)	(30,804,000$)	(26,261,000$)	(33,190,000$)	(29,979,000$)	(28,433,000$)	(23,910,000$)	(23,788,000$)	(21,659,000$)	(22,737,000$)	(18,252,000$)	(18,554,000$)	(18,370,000$)	(14,951,000$)	(17,833,000$)	(13,970,000$)	(8,895,000$)	(8,564,000$)
QoQ%			312.00%	48.36%	(4,744.15%)	(5.78%)	(11.44%)	1.01%	9.63%	(17.30%)	20.88%	(10.71%)	(5.44%)	(18.92%)	(.51%)	(9.83%)	4.74%	(24.57%)	1.63%	(1.00%)	(22.87%)	16.16%	(27.65%)	(57.06%)	(3.87%)
YoY%			5,709.72%	(2,848.89%)	(5,552.75%)	(5.46%)	(16.95%)	16.97%	7.14%	(8.34%)	(9.83%)	(39.52%)	(38.41%)	(25.05%)	(31.00%)	(28.21%)	(17.90%)	(52.08%)	(2.35%)	(32.81%)	(106.52%)	(74.58%)
Earnings Per Share, Basic			(7.93$)	(121.63$)	(12.56$)	(0.26$)	0.24$	(8.05$)	(0.41$)	(0.45$)	(0.39$)	(0.49$)	(0.45$)	(0.43$)	(0.53$)	(0.63$)	(0.58$)	(0.61$)	(0.48$)	(0.50$)	(0.50$)	(0.67$)	(54.87$)	(61.23$)	(56.85$)	(59.06$)
Earnings Per Share, Diluted			(7.93$)	(121.63$)	(12.56$)	(0.26$)	0.24$	(8.05$)	(0.41$)	(0.45$)	(0.39$)	(0.49$)	(0.45$)	(0.43$)	(0.53$)	(0.63$)	(0.58$)	(0.61$)	(0.48$)	(0.50$)	(0.50$)	(0.67$)	(54.87$)	(61.23$)	(56.85$)	(59.06$)
Unlevered FCF Per Share, Basic			0.11$	(8.07$)	(0.28$)	(0.25$)	0.19$	(6.81$)	(0.32$)	(0.45$)	(0.36$)	(0.42$)	(0.37$)	(0.37$)	(0.41$)	(0.51$)	(0.82$)	(0.67$)	(0.50$)	(0.49$)	(0.47$)	(0.85$)	(46.49$)	(43.10$)	(56.76$)	(45.72$)
Unlevered FCF Per Share, Diluted			0.11$	(8.07$)	(0.28$)	(0.25$)	0.19$	(6.81$)	(0.32$)	(0.45$)	(0.36$)	(0.42$)	(0.37$)	(0.37$)	(0.41$)	(0.51$)	(0.82$)	(0.67$)	(0.50$)	(0.49$)	(0.47$)	(0.85$)	(46.49$)	(43.10$)	(56.76$)	(45.72$)
Average Shares, Basic			-217,289,924	6,681,794	125,271,447	124,824,147	-126,011,503	3,423,499	68,299,170	68,030,966	67,861,326	67,607,713	67,033,150	66,265,703	45,466,157	38,009,022	37,437,063	37,293,438	37,691,464	36,934,311	36,843,087	22,263,994	325,018	228,144	156,454	145,016
Average Shares, Diluted			-217,289,924	6,681,794	125,271,447	124,824,147	-126,011,503	3,423,499	68,299,170	68,030,966	67,861,326	67,607,713	67,033,150	66,265,703	45,466,157	38,009,022	37,437,063	37,293,438	37,691,464	36,934,311	36,843,087	22,263,994	325,018	228,144	156,454	145,016
EBIT			1,722,858,000$	(812,684,000$)	(1,573,669,000$)	(32,486,000$)	(30,712,000$)	(27,559,000$)	(27,839,000$)	(30,804,000$)	(26,261,000$)	(33,190,000$)	(29,979,000$)	(28,433,000$)	(23,910,000$)	(23,788,000$)	(21,659,000$)	(22,737,000$)	(18,252,000$)	(18,554,000$)	(18,370,000$)	(13,723,000$)	(15,663,000$)	(11,785,000$)	(8,040,000$)	(7,849,000$)
EBITDA			1,722,858,000$	(812,684,000$)	(1,573,669,000$)	(32,486,000$)	(30,712,000$)	(27,559,000$)	(27,839,000$)	(30,804,000$)	(26,261,000$)	(33,190,000$)	(29,979,000$)	(28,433,000$)	(23,910,000$)	(23,788,000$)	(21,659,000$)	(22,737,000$)	(18,252,000$)	(18,554,000$)	(18,370,000$)	(13,723,000$)	(15,663,000$)	(11,785,000$)	(8,040,000$)	(7,849,000$)